| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Research Abstract |
The purpose of this study was to explore the predictive marker for liver injury caused by sorafenib-treatment. From the results using hepatoma cells, it showed that sorafenib itself was due to occurring liver injury. In addition, sorafenib N-oxide also showed cytotoxicity, which N-oxide might convert to sorafenib in cells. Sorafenib is metabolized to sorafenib N-oxide via CYP3A4 in human liver. Combined together, when CYP3A4 function decreased in a patient, sorafenib convert ration maintained high level in serum. Therefore, this pharmacokinetic profile may be a key role for causing liver injury.
|
